Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2001 3
2002 1
2008 2
2011 2
2012 12
2013 4
2014 2
2015 3
2016 2
2017 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Gubin MM, et al. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988. Nature. 2014. PMID: 25428507 Free PMC article.
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Matsushita H, et al. Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755. Nature. 2012. PMID: 22318521 Free PMC article.
Programmable nanoparticle functionalization for in vivo targeting.
Pan H, Myerson JW, Hu L, Marsh JN, Hou K, Scott MJ, Allen JS, Hu G, San Roman S, Lanza GM, Schreiber RD, Schlesinger PH, Wickline SA. Pan H, et al. FASEB J. 2013 Jan;27(1):255-64. doi: 10.1096/fj.12-218081. Epub 2012 Oct 9. FASEB J. 2013. PMID: 23047896 Free PMC article.
34 results